The Ruth and Bruce Faculty of Medicine, Technion Israel Institute of Technology, Efron St., POB 9649, Haifa 31096, Israel.
Curr Atheroscler Rep. 2011 Jun;13(3):215-24. doi: 10.1007/s11883-011-0170-7.
As atherosclerosis is still one of the major causes of death in Western populations, it is important to identify those individuals who are at increased risk for the disease so that aggressive treatment may be administered as early as possible. Following the understanding that oxidative stress has a pivotal role in the development and progression of atherosclerosis, many polymorphisms in genes that are related to redox systems were examined for their association with increased risk for cardiovascular disease (CVD). Although many polymorphisms were studied, only a handful showed consistent relevance to CVD in different trials. This article focuses on six of these polymorphisms, examining their effect on the risk for CVD as well as their effect on protein expression and function. Reports regarding pharmacogenetic implications of these polymorphisms, where such exist, are discussed as well.
由于动脉粥样硬化仍然是西方人群主要的死亡原因之一,因此识别那些患有这种疾病风险增加的个体非常重要,以便尽早进行积极治疗。在认识到氧化应激在动脉粥样硬化的发生和发展中起着关键作用之后,许多与氧化还原系统相关的基因中的多态性被检测其与心血管疾病 (CVD) 风险增加的相关性。尽管研究了许多多态性,但只有少数在不同试验中与 CVD 具有一致的相关性。本文重点介绍其中的六种多态性,研究它们对 CVD 风险的影响,以及它们对蛋白质表达和功能的影响。还讨论了这些多态性的药物遗传学意义的报告,如果存在的话。